GLP-1 franchise powers progress at Novo Nordisk in 2021
GLP-1 receptor agonist for chronic weight management - Clinical Advisor
Novo Nordisk comments on role of off-label use in Ozempic shortfall
Novo Nordisk 2018: Struggling against the tide – PharmaLive
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
Novo Nordisk 2022: Expanding capabilities – PharmaLive
FDA approves Novo Nordisk's GLP-1 drug Rybelsus for first-line type 2 diabetes treatment
Novo Nordisk looks to HEOR data to back Victoza | Pharmafile
Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article - KBR
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
FDA approves Novo Nordisk's semaglutide for weight management - Drug Discovery and Development
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
Novo Nordisk doesn't feel threatened by GLP-1 rival Lilly
FDA Approves Novo Nordisk's Saxenda as a Treatment for Chronic Weight Management
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo Nordisk's insulin pen receives EU approval to treat type 2 diabetes
Novo Nordisk Stock: Growing Obesity Epidemic Will Generate Demand (NYSE:NVO) | Seeking Alpha
Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought :: Scrip
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM
GLP-1: The Reliable Partner | circulatory system | GLP-1 is your reliable partner in treating type 2 diabetes. They work by mimicking the functions of natural incretin hormones -- including stimulating... | By Novo Nordisk | Facebook
Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company | Medgadget
